Immutep Receives ~AUD$1.13M R&D Tax Incentive
Portfolio Pulse from Benzinga Newsdesk
Immutep Limited has received a AUD$1.13M cash rebate from the Australian Federal Government's R&D tax incentive program. The rebate is for expenditure incurred on eligible R&D activities conducted in the 2022 fiscal year, mainly related to the Company's TACTI-002 and TACTI-003 clinical study using its lead compound eftilagimod alpha. The funds will be used to further its current active clinical trial programs for its lead product candidate, efti.
October 25, 2023 | 12:19 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Immutep Limited has received a significant cash rebate which will be used to further its clinical trial programs. This could potentially accelerate the development and eventual commercialization of its lead product candidate, efti.
The cash rebate received by Immutep Limited will provide additional funding for its clinical trial programs. This could potentially accelerate the development and eventual commercialization of its lead product candidate, efti, which would likely have a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100